April 26, 2023 C-Path Europe: A Global Vision of Success TUCSON, Ariz. and AMSTERDAM, April 26, 2023 — As an organization that generates regulatory-endorsed solutions and methodologies
March 29, 2023 C-Path Appoints Key Scientific Leaders to Executive Roles Critical Path Institute (C-Path) announced today the appointment of three accomplished leaders to key executive roles within the..
March 14, 2023 C-Path Welcomes BioCentury Inc. Co-Founder Bernstein to Board of Directors Dr. Bernstein will help steer the strategic vision of C-Path as the organization’s newest board member TUCSON, Ariz., March 14,
February 15, 2023 Airway Therapeutics Joins C-Path’s International Neonatal Consortium TUCSON, Ariz., February 15, 2023 — Critical Path Institute (C-Path) today announced that Airway Therapeutics, Inc. (“Airway”
January 25, 2023 C-Path Receives Letter of Support from EMA on Duchenne Muscular Dystrophy Clinical Trial Simulation Platform TUCSON, Ariz., Jan. 25, 2023 — Critical Path Institute (C-Path) today announced that the European Medicines Agency (EMA) has iss
December 20, 2022 C-Path’s Transplant Therapeutics Consortium Receives EMA Qualification Opinion for iBox Scoring System The iBox Scoring System is available for use in kidney transplant clinical trials as a novel secondary endpoint prognostic for all
December 20, 2022 C-Path Receives Letter of Support from EMA for Parkinson’s Disease Clinical Trial Simulation Platform TUCSON, Ariz., Dec. 20, 2022 — Critical Path Institute (C-Path) today announced that the European Medicines Agency (EMA) has iss
December 8, 2022 ‘Rare Disease Moonshot’ – Scaling-up public-private partnerships to accelerate research into world’s rarest diseases AMSTERDAM, Netherlands, December 8, 2022 — A new initiative to boost research and development into rare and paediatric diseases
December 1, 2022 C-Path and Ultragenyx Announce Data Sharing Agreement to Support Rare Disease Treatment and Novel Therapies TUCSON, Ariz., Dec. 1, 2022 — Critical Path Institute (C-Path) and Ultragenyx Pharmaceutical, Inc., (NASDAQ: RARE), a biopharmac